Has lung cancer immunotherapy entered era 2.0 / 医学研究生学报

American Society of Clinical Oncology has named immunotherapy 2.0 as the advance of this year recently .This se-lection is based on the recognition of the amazing progress achieved by the immunotherapy agents .Lung cancer is the leading cause of cancer death worldwide .Immunotherapy , along with traditional treatment strategies such as chemotherapy , radiation therapy and targe-ted therapy , provides patients of lung cancer with more possibilities .The new era of immunotherapy seems irresistible .